×
Log in
Get Started
Travel
Technology
Sports
Marketing
Education
Career
Social Media
+ Explore all categories
Report -
Program - K&M Congress · fortgeschrittenen NSCLC mit EGFR M+ Zugelassen als erste orale 1st line Monotherapie des NSCLC mit aktivierenden Mutationen der EGFR-TK1 (EGFR M+) Signifi
Select
Pornographic
Defamatory
Illegal/Unlawful
Spam
Other Terms Of Service Violation
File a copyright complaint
Please pass captcha verification before submit form